Aptose Biosciences shares to delist from Nasdaq as of April 2

Aptose Biosciences (APTO) announced that the Nasdaq Hearings Panel has determined to delist the common shares of the Company from The Nasdaq Stock Market. Under the terms of the Panel’s December 17, decision in this matter, the Company was required to demonstrate compliance with the Exchange’s equity requirement in Listing Rule 5550(b)(1) on or before March 31. As indicated in the Decision, March 31st represented the full extent of the Panel’s discretion to grant continued listing while the Company was non-compliant with the Equity Rule. On March 31, through its advisor, the Company confirmed that it had been unable to regain compliance with the Equity Rule by that date. Accordingly, the Panel has determined to delist the Company’s common shares from Nasdaq and will suspend trading in those securities effective at the open of business on April 2, 2025. The Company and board will review all available options, including an appeal to the determination, but will continue to execute its business plan and will seek to list on a U.S. national Securities Exchange at the appropriate time. Aptose’s shares remain listed on TSX under the symbol “APS”.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue